Pulse Biosciences, Inc. PLSE
Set alert
At close
Pre-market · Nov 2, 9:10 AM ET
- YTD
- +280.48%
- 1 year
- +208.56%
- Open
- 54.33
- Prev close
- 52.24
- Mkt cap
- 3.73B
- Vol
- 466.45K
- Avg vol
- 503.42K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 51.39
- High
- 54.70
- Forward P/E
- -44.65
- Beta
- 1.57
- Short ratio
- 5.88
- Inst. own
- 15.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 50.99
- 200-d avg
- 31.16
- 1y target
- 62.33
5D chart
Signals (136)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:55 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:20 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 10:05 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
3 days ago businesswire.com
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™)…
-
2 weeks ago benzinga.com
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the…
-
2 weeks ago benzinga.com
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
-
3 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.
1 month ago benzinga.com
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
1 month ago benzinga.com
This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.
-
1 month ago benzinga.com
BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70
BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $70.
-
1 month ago benzinga.com
Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold
On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distribution agreement (the "Sales Agreement") with Mizuho Securities USA LLC ("Mizuho") as sales agent,
-
1 month ago benzinga.com
Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones…
1 month ago benzinga.com
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
-
1 month ago benzinga.com
Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73
Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.
2 months ago benzinga.com
Top 3 Health Care Stocks That May Keep You Up At Night In Q3
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
2 months ago benzinga.com
This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets for PMT, ALAB.
2 months ago benzinga.com
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Workday downgraded, price target cut.
2 months ago benzinga.com
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's page. Analysts have positive views on ONTO stock.
-
2 months ago benzinga.com
Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58
Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $58.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $32 to $43.
-
2 months ago benzinga.com
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.28) per share from the…
4 months ago benzinga.com
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
-
5 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32
Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.
-
5 months ago benzinga.com
Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan…
-
6 months ago benzinga.com
Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation
The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research…
-
7 months ago benzinga.com
Pulse Biosciences' Long-Term AFib Clinical Data Demonstrates that Nanosecond Pulsed Field Ablation Delivers Speed, Safety, And Long-Term Durable Efficacy For Atrial Fibrillation (AFib).
Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and
-
7 months ago benzinga.com
Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
8 months ago benzinga.com
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
-
8 months ago benzinga.com
Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 16.13 percent increase over losses of…
-
8 months ago benzinga.com
Earnings Scheduled For February 19, 2026
Earnings Scheduled For February 19, 2026
8 months ago benzinga.com
A Glimpse of Pulse Biosciences's Earnings Potential
A Glimpse of Pulse Biosciences's Earnings Potential
8 months ago benzinga.com
What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences stock rises after new study data showed strong early results for its heart treatment device, helping shares outperform a weak broader market.
8 months ago benzinga.com
Pulse Biosciences Heart Device Data Fuels Stock Surge
Pulse Biosciences stock trading higher on promising clinical data for atrial fibrillation treatment, with potential for further growth.
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Strategy Posts Upbeat Q4 Results, Joins SunOpta, BILL Holdings, Mitek Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.
-
10 months ago benzinga.com
Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA…
-
12 months ago benzinga.com
Pulse Biosciences Q3 EPS $(0.29) Beats $(0.31) Estimate, Sales $86.000K Miss $500.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 38.1 percent decrease over losses of…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
Pulse Biosciences Announces Enrollment Of First Patient In NANOCLAMP AF Study For Treatment Of Atrial Fibrillation
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical ProcedurePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™…
-
1 year ago benzinga.com
Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology…
-
1 year ago benzinga.com
Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful…
-
1 year ago benzinga.com
Pulse Biosciences Announced A New Publication In The Journal Thyroid, The First-in-human Clinical Feasibility Study Demonstrates The Effectiveness Of Ablation Of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation (nsPFA) Energy
The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the treatment of symptomatic benign thyroid nodules with minimal side effects. The study was…
-
1 year ago benzinga.com
Pulse Biosciences Q2 EPS $(0.28) Misses $(0.26) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 40 percent decrease over losses of…
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
-
1 year ago benzinga.com
Oppenheimer Initiates Coverage On Pulse Biosciences with Outperform Rating, Announces Price Target of $22
Oppenheimer analyst Suraj Kalia initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Outperform rating and announces Price Target of $22.
-
1 year ago benzinga.com
Pulse Biosciences Q1 EPS $(0.25) Down From $(0.15) YoY
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.25) per share. This is a 66.67 percent decrease over losses of $(0.15) per share from the same period last year.
-
1 year ago benzinga.com
Pulse Biosciences: Nanosecond PFA Technology To Be Highlighted In Presentations And In Live Case Transmission Featuring nsPFA 360° Catheter Mapped With CARTO 3 Mapping System From Johnson & Johnson MedTech At HRS 2025 Annual Meeting
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmissionPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and…
-
1 year ago benzinga.com
Pulse Biosciences Q4 EPS $(0.31) Down From $(0.21) YoY
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.31) per share. This is a 47.62 percent decrease over losses of $(0.21) per share from the same period last year.